Meeting
2022 ASCO Annual Meeting
Characterization of genomic landscape using comprehensive circulating cell-free tumor DNA next generation sequencing in advanced thyroid carcinoma.
Authors
Valentina Tarasova
Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, FL
Valentina Tarasova , Jill Tsai , Bryan McIver , Julie E. Hallanger-Johnson , Colleen Veloski , Sarimar Agosto Salgado , Jude Masannat , Leylah Drusbosky , Christine H. Chung
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Circulating Biomarkers
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3045)
DOI
10.1200/JCO.2022.40.16_suppl.3045
Abstract #
3045
Poster Bd #
37
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
Correlative analysis of circulating tumor (ct) DNA and tumor mutational analysis (TMA) in patients with advanced pancreatobilliary malignancies (PBM).
First Author: Hani M. Babiker
Poster
2022 ASCO Annual Meeting
Novel use of ctDNA to identify muscle-invasive and non-organ-confined upper tract urothelial carcinoma.
First Author: Heather L Huelster
Poster
2022 ASCO Annual Meeting
Clinical utility of circulating tumor DNA sequencing with a large panel in patients with advanced soft-tissue sarcomas.
First Author: Julie Blanchi
Poster
2022 ASCO Genitourinary Cancers Symposium
Blood-based tumor mutational burden from circulating tumor DNA and immune checkpoint inhibitors in advanced prostate cancer.
First Author: Grant Rauterkus